Walgreens Lifts Guidance After Beating Earnings Estimates

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Walgreens Lifts Guidance After Beating Earnings Estimates

© Thinkstock

Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported third-quarter fiscal 2016 results before markets opened Wednesday. The drugstore chain reported adjusted diluted earnings per share (EPS) of $1.18 on net sales of $29.5 billion. In the same period a year ago, Walgreen reported EPS of $1.02 on revenue of $28.8 billion. Third-quarter results also compare to the consensus estimates for EPS of $1.14 and $29.71 billion in sales.

On a GAAP basis, the company posted net income of $1.1 billion in the first quarter ($1.01 per share). Net sales and earnings in the quarter “reflect fluctuations in the quarterly fair value adjustments of the company’s AmerisourceBergen Corporation warrants.”

Walgreens raised the low end of its fiscal year adjusted EPS guidance by 10 cents to a new range of $4.45 to $4.55. Guidance assumes no material help from the proposed acquisition of Rite Aid.

Consensus estimates for 2016 adjusted earnings called for EPS of $4.49. Analysts have also tabbed full-year revenues at $118.46 billion. For the company’s fourth quarter, consensus estimates call for EPS of $1.01 on revenues of $29.46 billion.

[nativounit]

Executive vice-chairman and CEO Stefano Pessina said:

I’m pleased to report that since the quarter end we achieved our goal set four years ago of at least $1 billion in combined net synergies in fiscal year 2016 related to the strategic combination with Alliance Boots. This provides us with a strong platform to further enhance operating performance, to meet the challenges of the current volatility in many of our markets and to better position our company for long-term success.

U.S. pharmacy sales totaled $21.2 billion in the quarter, up 3.7% year over year. Same-store sales rose 3.9%. Pharmacy sales accounted for 67.4% of total sales, up 5.8%, and same-store pharmacy sales rose 6%.

The company said its proposed acquisition of Rite Aid “is progressing as planned,” and Walgreens expects the transaction to close in the last half of this year.

Shares traded down about 0.6% in premarket trading Wednesday, at $83.01, in a 52-week range of $71.50 to $97.30. Thomson Reuters had a consensus analyst price target of $94.23 before the results were announced.

[wallst_email_signup]

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618